Click here to go to the previous page
Microdosing: Past Experience and Future Role in Translational Medicine
Program Code:
353
Date:
Wednesday, June 27, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Tal Burt, Duke Clinical Research Institute, United States
PRESENTER
(S):
Graham Lappin is the CSO for Xceleron and visiting professor of drug metabolism at the University of Lincoln. He also has his own consulting business called Isometix. Over the past 10 years he has developed many applications of AMS to drug development, particularly with clinical studies.
|
Joseph Bertino, Bertino Consulting, United States
Martin Bauer, Medical University of Vienna, Austria
Description
Microdosing holds the promise of increasing drug selection efficiency through the introduction of subpharmacological doses of test articles to humans. The session examines existing data, potential applications and future role of microdosing.
Learning Objectives:
Interpret pharmacokinetic (PK) and pharmacodynamic (PD) data from microdosing studies and appraise their relevance to pharmacological dose PK and PD estimates
Describe microdosing applications and their potential role in translational clinical research.